[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-332508-105":59,"doc-detail-332508-en":131},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":124,"head_meta":126,"extra_data":128,"updated_unix":130},105,"en","therapeutic-efficacy-of-il7ccl19-expressing-car-t-cells-in-intractable-solid-tumor-models-of-glioblastoma-and-pancreatic-cancer","Therapeutic Efficacy of IL7/CCL19-Expressing CAR-T Cells in Intractable Solid Tumor Models of Glioblastoma and Pancreatic Cancer","","Cancer immunotherapy combining immune checkpoint inhibitors with other anticancer strategies has gained traction across solid tumors, yet glioblastoma and pancreatic cancer remain highly resistant with poor outcomes. IL7/CCL19-producing next-generation CAR-T cells (7-19 CAR-T) were assessed in vitro and in vivo using EGFRvIII-positive glioblastoma models and HER2-positive pancreatic cancer organoids. 7-19 CAR-T showed antigen-specific cytotoxicity, triggered complete tumor rejection with extensive T-cell infiltration and prolonged survival in mice. These findings support IL7/CCL19 CAR-T as a potential therapeutic option.",{"@graph":69,"@context":123},[70,84,106],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/therapeutic-efficacy-of-il7ccl19-expressing-car-t-cells-in-intractable-solid-tumor-models-of-glioblastoma-and-pancreatic-cancer/332508/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/therapeutic-efficacy-of-il7ccl19-expressing-car-t-cells-in-intractable-solid-tumor-models-of-glioblastoma-and-pancreatic-cancer/332508.png","ImageObject",300,407,{"name":92,"@type":93},"Miles","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-08","2026-09-21",true,{"@type":102,"interactionType":103,"userInteractionCount":105},"InteractionCounter",{"@type":104},"ViewAction",12,{"@type":107,"mainEntity":108},"FAQPage",[109,115,119],{"name":110,"@type":111,"acceptedAnswer":112},"What therapeutic approach does the study evaluate?","Question",{"text":113,"@type":114},"The study evaluates next-generation CAR-T cells engineered to produce IL7 and CCL19 (7-19 CAR-T) for targeting glioblastoma and pancreatic cancer models.","Answer",{"name":116,"@type":111,"acceptedAnswer":117},"How were the CAR-T cells tested in this research?",{"text":118,"@type":114},"Cytotoxic activity and therapeutic effects were evaluated both in vitro and in vivo, using EGFRvIII-positive glioblastoma models and HER2-positive pancreatic cancer organoid models.",{"name":120,"@type":111,"acceptedAnswer":121},"What outcomes did the 7-19 CAR-T cells produce in glioblastoma and pancreatic cancer models?",{"text":122,"@type":114},"Anti-EGFRvIII 7-19 CAR-T induced antigen-specific cytotoxicity, complete rejection of glioblastoma with massive T-cell infiltration, and prolonged mouse survival; anti-HER2 7-19 CAR-T showed potent activity against autologous HER2-positive pancreatic cancer organoids with complete rejection and prolonged survival.","https://schema.org",{"og:url":83,"og:type":125,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":127,"canonical":83},"index,follow",{"doc_id":129,"site_id":62},332508,1790013050,{"code":4,"msg":5,"data":132},{"doc_id":129,"user_id":133,"nickname":92,"user_avatar":134,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":105,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":140,"language":141,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":142,"faqs":143,"seo_title":144,"seo_description":67,"update_tm":145,"read_time":146,"preview_page_count":4},13056703019404,"https://ap-avatar.wpscdn.com/davatar_29158cc5080c5b710cf443261637dec0","RESEARCH ARTICLE  [https://doi.org/10.1158/2767-9764.CRC-24-0226](https://doi.org/10.1158/2767-9764.CRC-24-0226)  OPEN ACCESS  \nTherapeutic Efficacy of IL7/CCL19-Expressing  CAR-T Cells in Intractable Solid Tumor Models of Glioblastoma and Pancreatic Cancer  \nKeisuke Ohta1,2, Yukimi Sakoda1, Keishi Adachi1, Taro Shinozaki3, Masao Nakajima2, Hiroyuki Yasuda3, Hiroaki Nagano2, and Koji Tamada1  \n􀀶  \nABSTRACT  \nCancer immunotherapy using immune checkpoint inhibitors and its combination with other anticancer therapies has emerged as a new standard of care because of the encouraging therapeutic effects in various solid cancers. Nonetheless, glioblastoma and pancreatic cancer remain resistant to immunotherapy and represent intractable cancers with the poorest prognosis. We investigated the therapeutic effects of nextgeneration chimeric antigen receptor (CAR) T cells producing IL7 and chemokine (C–C motif) ligand 19 (CCL19; referred to as 7 􀀃 19 CAR-T) in these intractable cancers. Cytotoxic activities and therapeutic effects of 7 􀀃 19 CAR-T were evaluated in vitro and in vivo, in a model using EGFR variant III (EGFRvIII)–positive glioblastoma and anti-EGFRvIII CAR-T generated from healthy donor peripheral blood mononuclear cells (PBMC), or a model using HER2-positive pancreatic cancer organoids and anti-HER2 CAR-T generated from the same patient’s PBMC. Anti-EGFRvIII 7 􀀃 19 CAR-T exhibited cytotoxic activity specific to EGFRvIII-positive tumor, induced complete rejection of glioblastoma with massive T-cell infiltration and tumor cell death in the tumor tissues, and consequently prolonged mouse survival. Anti-HER2 7 􀀃 19 CAR-T  \ndemonstrated a potent cytotoxic activity against autologous HER2-positive pancreatic cancer organoids and induced complete rejection of autologous tumor along with prolonged mouse survival. Our results suggest that 7 􀀃 19 CAR-T could become a therapeutic option for glioblastoma and pancreatic cancer. To the best of our knowledge, this is the first study to demonstrate the therapeutic efficacy of next-generation CAR-T in an autologous model using patient-derived tumor organoidsand CAR-T generated from the same patient’s PBMC, in which unwanted allogeneic immune responses are fully excluded.  \nSignificance: Despite the clinical development of CAR T-cell therapy, its efficacy in solid cancers has yet to be established. This study explored the therapeutic potential and immunologic mechanisms of IL7/CCL19-producing CAR-T therapy in preclinical solid cancer models of glioblastoma and pancreatic cancer. We found that IL7/CCL19-producing CAR-T cells generated from the patient’s PBMC showed potent therapeutic effects against the solid cancer model established by inoculating organoids from the autologous tumor tissue.  \nIntroduction  \nThe overall survival (OS) of various malignant tumors has been improved by recent advances in cancer immunotherapy using immune checkpoint inhibitors (ICI) and its combination with other anticancer drugs, which are currently approved as standardized treatments for patients with advanced cancer ( 1, 2).  \n1Department of ImmunologyYamaguchi University Graduate School of Medicine, Ube, Japan. 2Department of Gastroenterological, Breast and Endocrine Surgery, Yamaguchi University Graduate School of Medicine, Ube, Japan. 3Department of Pulmonary Medicine, Keio University School of Medicine, Shinjuku-ku, Tokyo. Corresponding Author: Koji Tamada, Department of Immunology, Yamaguchi University Graduate School of Medicine, 1-1-1 Minami-Kogushi, Ube 755-8505, Ja  \npan. E-mail: [ktamada@yamaguchi-u.ac.jp](ktamada@yamaguchi-u.ac.jp)  \n[doi:](doi: 10.1158/2767-9764)[ 10.1158/2767-9764](doi: 10.1158/2767-9764) .CRC-24-0226  \nThis open access article is distributed under the Creative Commons Attribution 4.0 International (CC BY 4. 0) license.  \n©2024 The Authors; Published by the American Association for Cancer Research  \nNonetheless, glioblastoma and pancreatic cancer still represent the intractable sol","cbCairwC5k1P62EG","https://ap.wps.com/l/cbCairwC5k1P62EG","pdf",14209678,11,"English","# Abstract\n# Significance\n# Introduction","[{\"question\":\"What therapeutic approach does the study evaluate?\",\"answer\":\"The study evaluates next-generation CAR-T cells engineered to produce IL7 and CCL19 (7-19 CAR-T) for targeting glioblastoma and pancreatic cancer models.\"},{\"question\":\"How were the CAR-T cells tested in this research?\",\"answer\":\"Cytotoxic activity and therapeutic effects were evaluated both in vitro and in vivo, using EGFRvIII-positive glioblastoma models and HER2-positive pancreatic cancer organoid models.\"},{\"question\":\"What outcomes did the 7-19 CAR-T cells produce in glioblastoma and pancreatic cancer models?\",\"answer\":\"Anti-EGFRvIII 7-19 CAR-T induced antigen-specific cytotoxicity, complete rejection of glioblastoma with massive T-cell infiltration, and prolonged mouse survival; anti-HER2 7-19 CAR-T showed potent activity against autologous HER2-positive pancreatic cancer organoids with complete rejection and prolonged survival.\"}]","Therapeutic Efficacy of IL7/CCL19-Expressing CAR-T Cells in Intractable Solid Tumor Models of Glioblastoma and Pancreatic Cancer | PDF",1789998546,28]